TrialAnnals of the rheumatic diseases2020

Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Claudia Kedor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.